RxDoctor Payments Data

Gregory Wood, MD

Cardiovascular Disease · Missoula, MTNPI 1487821344

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $5,100 of the $6,316 with a category attached, or 80.7%. Abbott accounts for 92.5% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $5,253 and has fallen 91.2% since, to $463 in 2025.

$6,316in general payments, 2019–2025

Across 22 payments — averaging $287.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$6K
  • Abiomed$333
  • Medtronic$41
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$35
  • Edwards Lifesciences$32
  • Scpharmaceuticals Inc.$17
  • plus $15 from 1 others
$61,407in research payments, 2019–2025

Across 21 payments — averaging $2924.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abbott$61K

What the payments were for

  • Consulting fees$5,10081%
  • Food & beverage$1,21619%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,316 in reported general payments places this provider in the 80th percentile of 49 cardiovascular disease providers in Montana.

See all cardiovascular disease providers in Montana

Medicare billing

Part B allowed, 2024
$83,796
Medicare patients
871
Services billed
1,351

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan223$211,224
EliquisApixaban142$168,690
JardianceEmpagliflozin98$107,409
BrilintaTicagrelor43$28,925
XareltoRivaroxaban22$28,335
FarxigaDapagliflozin Propanediol15$19,946
Metoprolol Succinate361$7,522
Torsemide130$4,100
Flecainide Acetate37$2,714
Carvedilol153$2,355
Potassium Chloride67$2,143
Spironolactone209$2,140
Atorvastatin Calcium149$2,007
Losartan Potassium135$1,507
Eplerenone12$1,241

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Missoula

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →